Results 171 to 180 of about 77,075 (344)

Malignant Pleural Effusion

American Journal of Respiratory and Critical Care Medicine
Sharma S, Arora RD, Boster J.
europepmc   +2 more sources

Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide

Cancer Medicine, Volume 15, Issue 4, April 2026.
This phase II trial investigated the safety and efficacy of opaganib in combination with abiraterone or enzalutamide in patients with castration‐resistant prostate cancer (CRPC). While the study did not meet its disease control efficacy endpoint, there was evidence of clinical activity in a subset of patients.
Jacqueline T. Brown, Bassel Nazha, Anna C. Ferreira, Kent Armeson, Elizabeth G. Hill, Besim Ogretmen, Shikhar Mehrotra, Alan Brisendine, George Magrath, Terry F. Plasse, Theodore Stewart Gourdin, Omer Kucuk, Michael Lilly   +12 more
wiley   +1 more source

Efficacy and Safety of Multivisceral Resection for Ovarian Cancer: A Comparative Study of Gynecologic Oncologists and Multidisciplinary Surgeons

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Background Advanced ovarian cancer often presents with extensive pelvic and abdominal metastases, even malignant pleural effusion. Consequently, multivisceral resection has become the common surgical approach to achieve optimal resection of ovarian cancer.
Luxin Ye, Qi Xue, Xianzhong Cheng, Ping Liu, Qian Zhao, Jiahui Chen, Xuening Wang, Yourong Chen, Xia Xu, Wenwen Guo, Jing Ni, Xiaoxiang Chen   +11 more
wiley   +1 more source

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Introduction and Methods Cancer therapy–related cardiac dysfunction (CTRCD) is a well established and potentially life‐threatening complication of contemporary oncologic treatment. Although comprehensive cardio‐oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent.
Abdelrahman Ali, Suparna C. Clasen, Anne Blaes, Stephen Casselli, Anita Deswal, Susan Halli Demeter, Gregory Durm, Anecita Fadol, Alessandra Ferrajoli, Michael G. Fradley, Joerg Herrmann, Borja Ibanez, Sue Koob, Bogda Koczwara, Kasey J. Leger, Jennifer E. Liu, Teresa López‐Fernández, Alexander R. Lyon, N. G. Choon Ta, John Teerlink, Eric H. Yang, Susan Dent, Daniel Lenihan   +22 more
wiley   +1 more source

Diagnostic Significance of Combining Telomerase Activity with CYFRA21-1 Level in Differentiating Malignant Pleural Effusion Caused by Lung Cancer from Benign Pleural Effusio

Chinese Journal of Lung Cancer, 2010
Background and objective Telomerase and CYFRA21-1 may be positively expressed in malignant pleural effusion, but the sensitivity and specificity of single tumor marker were low.
Hongmei LI, Junhua FU, Yuande XIU, Qinghua ZHOU   +3 more
doaj  

The Promise of Chemotherapy‐Free Strategies in Advanced Driver‐Negative NSCLC: A Systematic Review and Network Meta‐Analysis of Antiangiogenic Combination Therapies

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Background Antiangiogenic combination therapy—antiangiogenic agents combined with immune checkpoint inhibitors and/or chemotherapy—has become an important treatment strategy for advanced driver‐negative non‐small cell lung cancer (NSCLC). We conducted a network meta‐analysis to compare efficacy and safety and identify optimal antiangiogenic ...
Zirui Li, Weixing Zhao, Wanjing Guo, Xinxin Lu, Chenyu Jia, Jiayun Ma, Qi Zhou, Xiujin Yang, Jun Jiang   +8 more
wiley   +1 more source

Sustained Belinostat‐Induced Metabolic Response and Tolerability in Heavily Pretreated Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Angioimmunoblastic T‐cell lymphoma (AITL), a rare and aggressive subtype of peripheral T‐cell lymphoma (PTCL), often demonstrates resistance to standard therapies. The optimal therapeutic approach for relapsed/refractory (R/R) AITL remains therefore uncertain and challenging, with an unmet need for effective treatment options.
Vassiliki Labropoulou, Evgenia Verigou, Eleni P. Kourea, Maria Liga, Dimitrios Tsokanas, Krisela‐Christina Valera, Alexandros Spyridonidis   +6 more
wiley   +1 more source

The use of thrombolytics in the management of complex pleural fluid collections [PDF]

, 2017
Bahjri, Khaled, Copeland, Hannah, Duldulao, Marjulin, Heimes, Jessica, Lulla, Aditya, Wallen, Jason M, Zaheer, Salman   +6 more
core   +2 more sources

Giant Ovarian Leiomyoma Presenting With Unusual Lower Limb Weakness and Paresis: A Case Report

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Ovarian leiomyomas are rare, benign tumors accounting for 0.5%–1% of all benign ovarian neoplasms, typically presenting asymptomatically or with nonspecific symptoms such as abdominal pain. Neurological symptoms, such as lower limb weakness and paresis, are exceptionally rare and have not been previously reported as primary manifestations of ...
Bahar Amiri, Maryam Moghbel Baerz, Arian Karimi Rouzbahani, Arya Behzadi, Zahra Haghighatian   +4 more
wiley   +1 more source

Chemical Pleurodesis for Malignant Pleural Effusion: How Far Have We Come in 80 Years? [PDF]

, 2015
Coenraad F.N. Koegelenberg, Morné J. Vorster   +1 more
openalex   +1 more source